Abbott Laboratories (ABT)

Market Cap	188.52B -22.5%
Revenue (ttm)	44.33B +5.7%
Net Income	6.50B -51.3%
EPS	3.72 -51.3%
Shares Out	1.74B
PE Ratio	29.16
Forward PE	19.11
Dividend	$2.52 (2.28%)
Ex-Dividend Date	Apr 15, 2026

Volume	8,240,777
Open	109.50
Previous Close	110.71
Day's Range	107.75 - 109.95
52-Week Range	105.27 - 139.06
Beta	0.74
Analysts	Strong Buy
Price Target	139.38 (+28.47%)
Earnings Date	Apr 15, 2026

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1888
• Employees: 115,000
• Stock Exchange: NYSE
• Ticker Symbol: ABT
• Website: https://www.abbott.com

Financial Performance

In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.

Analyst Summary

According to 16 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $139.38, which is an increase of 28.47% from the latest price.

Price Target

$139.38

(28.47% upside)

Analyst Consensus: Strong Buy